Compare TLF & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLF | ALLR |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 19.3M |
| IPO Year | 2006 | 2021 |
| Metric | TLF | ALLR |
|---|---|---|
| Price | $2.38 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 70.7K | ★ 187.0K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | ★ 31.65% | N/A |
| EPS Growth | ★ 1122.22 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $76,324,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.15 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $2.28 | $0.61 |
| 52 Week High | $3.78 | $2.35 |
| Indicator | TLF | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 22.59 | 50.97 |
| Support Level | N/A | $0.80 |
| Resistance Level | $2.88 | $1.14 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 7.95 | 66.61 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.